Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Stock Has Consensus Target Price of $8.75 According to Brokerages

Posted by Geri Gentry on Oct 25th, 2026

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Free Report) has received a consensus rating of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $8.33.

Several analysts recently weighed in on the company. Chardan Capital reissued a “buy” rating on shares of Rani Therapeutics in a report on Thursday. HC Wainwright restated a “buy” rating on shares of Rani Therapeutics in a research report on Tuesday, October 6th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Rani Therapeutics in a research report on Thursday, October 15th.

Read Our Latest Research Report on RANI

Rani Therapeutics Price Performance

Shares of Rani Therapeutics stock opened at $0.61 on Friday. Rani Therapeutics has a 1-year low of $0.57 and a 1-year high of $2.63. The business has a 50-day moving average of $0.79 and a 200-day moving average of $0.83. The company has a market capitalization of $84.46 million, a PE ratio of -2.24 and a beta of 0.69.

Rani Therapeutics (NASDAQ:RANI – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The business had revenue of $1.71 million during the quarter, compared to analyst estimates of $0.93 million. On average, equities analysts expect that Rani Therapeutics will post -0.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Rani Therapeutics

Hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC grew its holdings in Rani Therapeutics by 155.5% during the second quarter. Squarepoint Ops LLC now owns 41,902 shares of the company’s stock worth $32,000 after acquiring an additional 25,501 shares during the period. Kestra Private Wealth Services LLC increased its stake in Rani Therapeutics by 4.1% in the 1st quarter. Kestra Private Wealth Services LLC now owns 265,159 shares of the company’s stock valued at $195,000 after buying an additional 10,347 shares during the period. Finally, AWM Investment Company Inc. purchased a new stake in shares of Rani Therapeutics during the second quarter worth $5,703,000. 30.19% of the stock is currently owned by institutional investors and hedge funds.

Rani Therapeutics Company Profile

(Get Free Report)

Rani Therapeutics Holdings, Inc is a clinical-stage biotherapeutics company developing technology designed to deliver biologic medicines orally. Its proprietary RaniPill platform is an ingestible robotic capsule intended to transport biologic drugs through the stomach and release them into the small intestine, where they can be absorbed into the bloodstream. The approach is intended to address the limitations of many biologic therapies, which are commonly administered by injection or infusion.

The company is advancing the RaniPill platform for potential use with a range of large-molecule medicines, including peptides, proteins and antibodies.